Aptamer–drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity

References

• SingalPKLiiskovicNSHillMThomasTPLiTCombination therapy with probucol prevents adriamycininduced cariomyopathyMol Cell Cardiol19952710551063
   PubMed Web of Science ®Google Scholar
• FridrikMAJaegerUPetzerACardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: a randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14)Eur J Cancer20165811212126990931
   PubMed Web of Science ®Google Scholar
• HarringtonKJRowlinson-BuszaGSyrigosKNVileRGUsterPSPetersAMStewartJSPegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumoursClin Cancer Res20006124939494911156255
   PubMed Web of Science ®Google Scholar
• YangJQiaoLZengZThe role of the ATM/Chk/P53 pathway in mediating DNA damage in hand-foot syndrome induced by PLDToxicol Lett20174265131139
   Google Scholar
• YokomichiNNagasawaTColer-ReillyAPathogenesis of hand-foot syndrome induced by PEG-modified liposomal doxorubicinHum Cell201326181823386177
   PubMed Web of Science ®Google Scholar
• RohlfingSAurichMSchöningTHoADWitzens-HarigMNonpegylated liposomal Doxorubicin as a component of R-CHOP is an effective and safe alternative to conventional Doxorubicin in the treatment of patients with diffuse large B-cell lymphoma and preexisting cardiac diseasesClin Lymphoma Myeloma Leuk201515845846325899891
   PubMed Web of Science ®Google Scholar
• CallahanRAdo-trastuzumab emtansine in metastatic HER2-positive breast cancerJ Adv Pract Oncol20145213413925032047
   PubMedGoogle Scholar
• UppalHDoudementEMahapatraKPotential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)Clin Cancer Res201521112313325370470
   PubMed Web of Science ®Google Scholar
• ChenKLiuBYuBAdvances in the development of aptamer drug conjugates for targeted drug deliveryWiley Interdiscip Rev Nanomed Nanobiotechnol201793 Epub10312016
   Web of Science ®Google Scholar
• ZhaoNPeiSNQiJOligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemiaBiomaterials201567425126204224
   PubMed Web of Science ®Google Scholar
• ZhuCLSongXYZhouWHYangHHWenYHWangXRAn efficient cell-targeting and intracellular controlled-release drug delivery system based on MSN-PEM-aptamer conjugatesJ Mater Chem20091977657770
   Web of Science ®Google Scholar
• GalaKChandarlapatySMolecular pathways: HER3 targeted therapyClin Cancer Res20142061410141624520092
   PubMed Web of Science ®Google Scholar
• CampbellMRAminDMoasserMMHER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancertherapyClin Cancer Res20101651373138320179223
   PubMed Web of Science ®Google Scholar
• ZhangJZhangXLiuQMammalian cell display for rapid screening scFv antibody therapyActa Biochim Biophys Sin2014461085986625246434
   PubMedGoogle Scholar
• LiuYJDouXQWangFIL-4RJ aptamer-liposome-CpG oligodeoxynucleotides suppress tumour growth by targeting the tumour microenvironmentJ Drug Target2016119
   Google Scholar
• DichevaBMSeynhaeveALSoulieTEggermontAMTen HagenTLKoningGAPharmacokinetics, tissue distribution and therapeutic effect of cationic thermosensitive liposomal doxorubicin upon mild hyperthermiaPharm Res201633362763826518763
   PubMed Web of Science ®Google Scholar
• BatesPJLaberDAMillerDMThomasSDTrentJODiscovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancerExp Mol Pathol200986315116419454272
   PubMed Web of Science ®Google Scholar
• KimJHImKSKimNHYheeJYNhoWGSurJHExpression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: histopathological and immunohistochemical studyVet J2011189331832220947393
   PubMed Web of Science ®Google Scholar
• TrocméEMougiakakosDJohanssonCCNuclear HER3 is associated with favorable overall survival in uveal melanomaInt J Cancer201213051120112721484789
   PubMed Web of Science ®Google Scholar
• Little field PLiuLMysoreVShanYShawDEJuraNStructural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutationsSci Signal20147354ra11425468994
   PubMed Web of Science ®Google Scholar
• BielackSSErttmannRWinklerKLandbeckGDoxorubicin: effect of different schedules on toxicity and anti-tumor efficacyEur J Cancer Clin Oncol19892558738822661240
   PubMedGoogle Scholar
• YildirimYGultekinEAvciMEInalMMYunusSTinarSCardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancerInt J Gynecol Cancer200818222322717511800
   PubMed Web of Science ®Google Scholar
• YuanYOrlowSJCurtinJDowneyAMuggiaFPegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligoEcancermedicalscience2008211122275986
   PubMedGoogle Scholar
• ShimadaMSatoSOtsukiTSupportive care for hand-foot syndrome and stomatitis in relapsed ovarian cancer patients receiving pegylated liposomal doxorubicinJ Clin Oncol201129e19722
   Web of Science ®Google Scholar
• von GruenigenVFrasureHFuscoNDeBernardoREldermireEEatonSWaggonerSA double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patientsCancer2010116204735474320629022
   PubMed Web of Science ®Google Scholar
• ZajaFTomadiniVZaccariaACHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patientswith diffuse large B-cell lymphomaLeuk Lymphoma200647102174218017071492
   PubMed Web of Science ®Google Scholar
• OkiYEwerMSLenihanDJPegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trialClin Lymphoma Myeloma Leuk201515315215825445468
   PubMed Web of Science ®Google Scholar
• BulbakeUDoppalapudiSKommineniNKhanWLiposomal formulations in clinical use: an updated reviewPharmaceutics20179212
   PubMed Web of Science ®Google Scholar
• LeeCHLeeSHKimJHNohYHNohGJLeeSWPharmacokinetics of a cholesterol-conjugated aptamer against the hepatitis C virus (HCV) NS5B proteinMol Ther Nucleic Acids2015410e25426440598
   PubMedGoogle Scholar
• LealMWentlandJHanXPreclinical development of an anti-5T4 antibody−drug conjugate: pharmacokinetics in mice, rats, and NHP and tumor/tissue distribution in miceBioconjug Chem201526112223223226180901
   PubMed Web of Science ®Google Scholar